Veru reports record fiscal 2021 full-year financial results

--fy21 net revenues increase 44% to $61 million and gross profit increases 56% to $48 million, achieving new historical highs-- --phase 3 sabizabulin covid-19 clinical study for treatment of hospitalized moderate to severe covid-19 patients at high risk for acute respiratory distress syndrome being conducted in us, mexico, south america, and europe; clinical results expected 1h 2022--
VERU Ratings Summary
VERU Quant Ranking